E*TRADE Financial Corporation (NASDAQ:ETFC) Files An 8-K Regulation FD Disclosure

E*TRADE Financial Corporation (the “Company”) is presenting at the Raymond James Institutional Investors Conference today. During the presentation, the Company will discuss its Daily Average Revenue Trades (DARTs) for the month of February. For February 2018, the Company reports preliminary DARTs of 330,000, a 5 percent increase from January. Derivatives represented 31 percent of total preliminary DARTs in February, an increase of 70 basis points from the prior month. The Company intends to issue its standard monthly activity report for February on or about March 14, 2018.

The information appearing in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD.

About E*TRADE Financial Corporation (NASDAQ:ETFC)
E*Trade Financial Corporation is a financial services company. The Company provides brokerage and related products and services primarily to individual retail investors under the brand E*TRADE Financial. The Company also provides investor-focused banking products, primarily sweep deposits, to retail investors. The Company operates in two segments: trading and investing, and balance sheet management. Its trading and investing segment offers a suite of financial products and services to individual retail investors. Its balance sheet management segment focuses on asset allocation and managing credit, liquidity and interest rate risks. Its hybrid service delivery model is delivered through various digital platforms: E*TRADE.com, E*TRADE Mobile and E*TRADE Pro. E*TRADE.com is its site that provides customers with tools, guidance, actionable ideas, research and education to take control of their finances. E*TRADE Mobile offers trading applications for various smartphones and tablets.